Amicus Therapeutics, Inc.
FOLDAmicus Therapeutics, Inc. is an American biopharmaceutical company based in Princeton, New Jersey. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates. As of April 2026, Amicus Therapeutics is a subsidiary of BioMarin Pharmaceutical.
Drugs in Pipeline
11
Phase 3 Programs
7
Upcoming Catalysts
5
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
5 upcoming, 0 past
How FOLD's past catalysts played out
Miglustat
Pompe Disease (Late-onset)
AT2221
Pompe Disease (Late-onset)
Cipaglucosidase Alfa
Pompe Disease (Late-onset)
Migalastat HCl 20 mg
Fabry Disease
migalastat hydrochloride
Fabry Disease
ATB200
Pompe Disease
migalastat HCl 150 mg
Fabry Disease
Afegostat tartrate
Gaucher Disease, Type 1
Agalsidase Beta
Fabry Disease
migalastat HCl
Fabry Disease
duvoglustat
Pompe Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Miglustat | Phase 3 | Pompe Disease (Late-onset) | - | Patent 2038 |
AT2221 | Phase 3 | Pompe Disease (Late-onset) | - | - |
Cipaglucosidase Alfa | Phase 3 | Pompe Disease (Late-onset) | - | - |
Migalastat HCl 20 mg | Phase 3 | Fabry Disease | - | - |
migalastat hydrochloride | Phase 3 | Fabry Disease | - | - |
ATB200 | Phase 3 | Pompe Disease | - | - |
migalastat HCl 150 mg | Phase 3 | Fabry Disease | - | - |
Afegostat tartrate | Phase 2 | Gaucher Disease, Type 1 | - | - |
Agalsidase Beta | Phase 2 | Fabry Disease | - | - |
migalastat HCl | Phase 2 | Fabry Disease | - | - |
duvoglustat | Phase 2 | Pompe Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Amicus Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Amicus Therapeutics, Inc.'s (FOLD) pipeline across Phase 3, Phase 2. Its lead program is Miglustat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amicus Therapeutics, Inc.'s next FDA catalyst?→
Amicus Therapeutics, Inc.'s (FOLD) next tracked catalyst is a Phase 3 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track FOLD biotech catalysts?→
Add FOLD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amicus Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.